Pulmonx Corporation Q3 2024 Earnings Report

Pulmonx Corporation (ticker: LUNG) announced its third-quarter earnings on October 30, 2024, revealing a 15% year-over-year increase in worldwide sales, totaling $20.4 million. The U.S. market contributed significantly with a 17% rise in revenue, while international sales grew by 12%.

The company reaffirmed its full-year revenue guidance, showing confidence in continued growth, especially in international markets. Pulmonx emphasized its strategic focus on physician training, patient workflow automation, and raising awareness of its Zephyr Valves for COPD treatment.

Key Takeaways

• Q3 worldwide sales: $20.4 million, a 15% increase year-over-year.
• U.S. revenue: $13.8 million (up 17%); International sales: $6.6 million (up 12%).
• Full-year revenue guidance: $81 million to $84 million.
• Focus on training physicians, automation, and increasing product awareness.
• Progress in clinical trials with the AeriSeal program set for commercial launch outside the U.S. in 2026 and in the U.S. by 2027.

Company Outlook

• Management anticipates a 20% growth midpoint for full-year 2024 revenue.
• Confidence in international market growth, including China and Europe.
• Expected growth catalysts for 2025 and beyond.

Financial Summary

• Net loss for the quarter: $14.1 million, with a slight year-over-year improvement.
• Operating expenses increased by 3% to $29.2 million.
• Gross margin stable at 74%.
• Operating expenses reduced by approximately $5 million, highlighting decreased stock-based compensation.

Q&A Highlights

• Discussions focused on strategic initiatives and economic benefits for underserved patient populations.

Pulmonx has demonstrated resilience and strategic foresight in its third-quarter performance, with solid sales growth and a commitment to market expansion. Its focus on training, automation, and promoting Zephyr Valves positions it well within the COPD treatment landscape. Advancements in clinical trials for AeriSeal also suggest future potential, with notable patient benefits observed. Despite a reported net loss, the company's expense management and steady gross margin indicate sound financial control. Investors will closely monitor Pulmonx as it implements growth strategies, particularly with the anticipated commercial launches of the AeriSeal program.

InvestingPro Insights

Pulmonx’s earnings report reflects significant metrics and insights from InvestingPro, with a 15% year-over-year increase in sales, and revenue growth of 26.26% over the last twelve months. Despite challenges in profitability and a $14.1 million net loss, the company’s strong gross profit margin at 74.19% and solid cash position indicate potential for navigating challenges ahead.

Conclusion

Pulmonx continues to progress strategically, with strong engagement in education programs and favorable clinical data enhancing its market position. Management is optimistic about the growth trajectory, particularly in international markets, setting the stage for future expansions.

This article was generated with AI support and reviewed by an editor. For more information see our T&C.